{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-22-000065","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.860106+00:00","generated_at":"2026-06-24T02:10:41.007109+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allogene expects FDA clearance for first allogeneic CAR T pivotal trial; Q2 net loss $74.8M","bullets":["FDA clearance expected in coming weeks for Phase 2 pivotal trial of ALLO-501A in LBCL; would be first allogeneic CAR T pivotal trial.","Ended Q2 2022 with $686M cash, cash equivalents and investments; net loss $74.8M ($0.52 per share).","Full year GAAP OpEx guided to low end of $360M-$390M; cash burn ~$250M for 2022.","CF1 manufacturing facility operational; projected capacity ~20,000 doses/year; earned LEED Gold designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-22-000065","json":"https://secwatch.observer/filing/0001737287-22-000065.json","markdown":"https://secwatch.observer/filing/0001737287-22-000065.md","text":"https://secwatch.observer/filing/0001737287-22-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000065/0001737287-22-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000065/allo-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:10:41.007109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}